The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from Helicobacter pylori activates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3+ TReg cells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived from Helicobacter pylori partially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.
发明者证明,用源自幽门螺杆菌的
糖脂治疗幼年哺乳小鼠会以CD1d限制方式激活NKT细胞,并在过敏原诱导的哮喘模型中对AHR具有保护作用。发明者进一步发现,这种保护效应可以通过暴露于
糖脂的NKT细胞转移,并与抑制性双阴性NKT细胞和Foxp3+ TReg细胞的扩增相关。发明者还在此证明,用源自幽门螺杆菌的
糖脂对成年小鼠进行预处理部分抑制气道高反应性,并在
臭氧暴露模型中抑制BAL炎症。因此,本文提供了用于治疗和预防炎症性疾病(如哮喘或自身免疫疾病)的组合物和方法,适用于需要的受试者。